Increases in CSF levels of phosphorylated tau at T181, T217, and T231 in early preclinical AD stages can accurately differentiate between Aβ PET-positive and Aβ PET-negative individuals (Suarez-Calvet et al., 2020). The gene discussed is MAPT; the disease is Alzheimer disease.